Blanche vows federal action on mail‑order abortion pills, setting up the next legal fight over mifepristone

Acting U.S. Attorney General Todd Blanche told thousands of faith leaders he will take action to restrict mail‑order access to abortion medication, signaling a forthcoming federal enforcement posture that could affect how pills are prescribed and shipped nationwide, according to a report published by the Arizona Mirror on Aug. 4 (https://azmirror.com/2026/08/04/repub/ag-nominee-todd-blanche-tells-faith-leaders-he-will-take-action-to-restrict-abortion-drug-access/).

Blanche’s remarks came July 30 on a White House Faith Office call, days before the Judiciary Committee advanced his nomination on a party‑line vote. On the call, he said he was committed to policy solutions so that the U.S. Supreme Court’s Dobbs decision “becomes permanent in every single state,” the Mirror reported. A recording posted by Intercessors of America was publicly available on YouTube earlier Tuesday before being removed later that afternoon, according to the same report.

The immediate consequence, if implemented, would be a federal challenge to the mail‑order and telehealth model that has allowed mifepristone to reach patients without an in‑person visit under an FDA policy first loosened in 2023. The Mirror noted that people in states with abortion bans have used telehealth providers in states without bans to obtain the drug by mail.

Blanche told participants he is working “hand in hand” with the U.S. Department of Health and Human Services, the U.S. Food and Drug Administration and President Donald Trump’s White House team to fulfill those goals. “If states have said, ‘We are going to protect the unborn and we’re going to protect every life from the moment of conception,’ we’re putting practices and policies in place so that other states and other organizations can’t attack that and they can’t do things like they’re doing with mail‑order drugs,” he said, per the Mirror’s account.

The policy backdrop includes a Louisiana lawsuit seeking to rescind the FDA’s 2023 change that allowed dispensing mifepristone without an in‑person visit, and an ongoing FDA safety review of mifepristone that the agency has said will not be completed until at least December, the Mirror reported. Health care providers who support abortion have said they intend to continue prescribing misoprostol even if mifepristone access narrows.

Anti‑abortion activists have also urged the administration to enforce the Comstock Act, an 1873 statute that prohibits mailing items “designed, adapted, or intended for preventing conception or producing abortion.” The Mirror reported that Blanche did not mention Comstock on the call but has been pressured by such groups to do more.

From a legal perspective, any federal move to curtail mail‑order dispensing will test several fault lines at once: the scope of FDA’s authority and its 2023 policy, the interplay of federal criminal statutes governing the mails, and the extent to which interstate telehealth models can be limited by federal enforcement. Those questions will determine both the appropriate remedy and the durability of any action the Justice Department attempts.

The timing Blanche described is assertive, but the record cited by the Mirror points to procedural constraints. The FDA review is still pending, the Louisiana challenge is active, and activists are seeking a separate Comstock pathway that Blanche did not endorse on the call. Each route carries different litigation risks and costs.

For Arizona readers, the mail‑order issue matters because it has defined post‑Dobbs access strategies and enforcement debates. If DOJ, HHS and FDA align to narrow or police shipping channels, state actors and providers will be adjusting compliance in real time and the courts will be the venue where those lines are drawn.

Blanche told faith leaders, “We don’t have complete victory yet, but we will have victory, and victory will be soon and it will be permanent,” the Mirror reported. His Senate confirmation now becomes the next procedural step before any coordinated federal action can move from rhetoric to rule, guidance, or enforcement.